Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TBLT > ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ: TBLT; TBLTW), announced today that the Company has started to sell 93 ToughBuilt products on Amazon.It (Italy) and Amazon.de (Germany).
TBLT > 8.05
MAIA up 21% @ 7.03 > recent IPO
MAIA Biotechnology Announces Pricing of Initial Public Offering
7:52 pm ET July 27, 2022 (BusinessWire) Print
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less discounts and commissions, to cover over-allotments.
The shares of common stock are expected to begin trading on the NYSE American under the ticker symbol "MAIA" on July 28, 2022. The offering is expected to close on August 1, 2022, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company's product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes.
ThinkEquity is acting as sole book-running manager for the offering.
The registration statement on Form S-1 (file No. 333-264225) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and became effective on July 27, 2022. A final prospectus related to the proposed offering will be filed and made available on the SEC's website at https://www.sec.gov/. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006179/en/
SOURCE: MAIA Biotechnology, Inc.
Investor Inquiries
ICR Westwicke
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282
MAIA Biotechnology, Inc. is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. The Company’s pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers. The Company's THIO (6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is a telomere-by-telomerase targeting agent for the treatment of multiple cancer types. THIO is followed by Libtayo for the treatment of advanced non-small-cell lung cancer. The Company's 2nd-generation program is engaged in discovering new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. The 2nd-generation pipeline of potential telomere-targeting agents includes five compounds that have undergone in vitro inhibitory testing in five cancer models. The Company's subsidiary is MAIA Biotechnology Australia Pty Ltd.
Gainers Premarket:
MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.
Aethlon Medical, Inc. (NASDAQ: AEMD) rose 33% to $1.33 in pre-market trading after dropping over 7% on Friday.
GeoVax Labs, Inc. (NASDAQ: GOVX) rose 32.2% to $3.61 in pre-market trading amid continued strength in monkeypox names. The company also recently announced the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara vectored vaccine against Sudan ebolavirus.
Celyad Oncology SA (NASDAQ: CYAD) rose 31.5% to $2.29 in pre-market trading after the company said that the FDA has lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial.
Mobile Global Esports Inc. (NASDAQ: MGAM) rose 31.1% to $14.67 in pre-market trading after jumping around 180% on Friday. Mobile Global Esports priced its IPO at $4 per share.
AIM ImmunoTech Inc. (NYSE: AIM) rose 23.3% to $0.90 in pre-market trading. AIM ImmunoTech, last week, reported positive pilot study data from expanded access program evaluating ampligen for the treatment of long COVID-19.
Lottery.com Inc. (NASDAQ: LTRY) rose 20.8% to $0.3565 in pre-market trading. Lottery.com shares tumbled around 64% on Friday after the company in an SEC filing said its board determined it does not have sufficient financial resources to fund operations.
Virax Biolabs Group Limited (NASDAQ: VRAX) rose 19.3% to $6.44 in pre-market trading after declining 74% on Friday.
Athersys, Inc. (NASDAQ: ATHX) rose 18.7% to $0.2958 in pre-market trading. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
MediaCo Holding Inc. (NASDAQ: MDIA) rose 15% to $2.36 in pre-market trading. MediaCo Holding) 10% owner Soohyung Kim bought a total of 12,899,480 shares at an average price of $2.32.
Redbox Entertainment Inc. (NASDAQ: RDBX) rose 14.9% to $5.01 in pre-market trading after declining around 15% on Friday.
Orchard Therapeutics plc (NASDAQ: ORTX) rose 14.5% to $0.6068 in pre-market trading after declining around 4% on Friday.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares rose 13.4% to $0.8990 in pre-market trading after jumping over 51% on Friday. The U.S. Food and Drug Administration, last month, declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceuticals’ lead drug ZYESAMI (aviptadil) for subgroup of patients with critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir.
36Kr Holdings Inc. (NASDAQ: KRKR) rose 11.3% to $1.28 in pre-market trading after gaining more than 9% on Friday.
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) rose 10.9% to $0.9650 in pre-market trading after dropping over 9% on Friday.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) rose 10.1% to $1.85 in pre-market trading after dropping 10% on Friday. Tonix Pharmaceuticals recently announced a collaboration with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study to develop TNX-801 as a vaccine to protect against monkeypox and smallpox.
SIGA Technologies, Inc. (NASDAQ: SIGA) rose 9.7% to $18.86 in pre-market trading. SIGA Technologies shares dropped sharply on Friday after the FDA announced there is currently no human data demonstrating the efficacy of Tpoxx for the treatment of Monkeypox.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 9.5% to $0.81 in pre-market trading. Creative Medical Technology recently reported positive top-line results for OvaStem® pilot study.
Statera Biopharma, Inc. (NASDAQ: STAB) rose 9.2% to $0.2290 in pre-market trading.
Fathom Digital Manufacturing Corporation (NYSE: FATH) rose 7.5% to $4.60 in pre-market trading.
Aaron Judge seems to know what he wants. > A bidding bidding war come 2023.
.05+ close! > Get ready for Fusion Specialty Pharmacy a nationally accredited compounding pharmacy licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications. Fusion generated $3,801,497 in 2021.
Agree!
"Emergent Health (OTCMKTS: EMGE) continues to make steady gains up the charts in recent trading running all of last week and closing the week off strong up 25% on Friday on $1 million in dollar volume. The stock is under heavy accumulation and is quickly turning into one of the top most searched for stocks on the OTC. Blessed with a tight share structure EMGE is one reverse merger that has not disappointed so far and has a lot of room to grow. EMGE is now closing on the acquisition of Regen Biowellness, Inc. a distributor of various products in the plant-based and regenerative medical fields and bringing on executive Jim Morrison, the former president of L’Oréal as the new CEO of Emergent upon the acquisition of Evolutionary Biologics, expected to close within the next three weeks. Emergent plans to create a complete human and pet portfolio and become a major participant in the field of OTC human and pet products. Fusion Specialty Pharmacy is a nationally accredited compounding pharmacy licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications. Fusion generated $3,801,497 in 2021 Revenues, an approximate 100% increase from 2020 Revenues of $1,971,599. New CEO Jim Morrison has big plans for Emergent including continued growth through acquisition, becoming fully reporting and uplisting to the big boards. "
EMGE IS A GREAT $$$$$ OPPORTUNITY!
Exponential catalysts > ignition > Blastoff of EMGE > AUGUST!!!!!
Emergent is scheduled to close the acquisitions of Regen Biowellness on Monday August 1st, 2022, Evolutionary Biologics within the next two weeks and Fusion Specialty Pharmacies during this quarter.
Multiple closings > August > $$$$$
EMGE
Emergent's Pending Acquisition "Evolutionary Biologics" Engages "Aesthetics By Design" to Market, Sell and Distribute Regenerative Medicine Products Produced by Evolutionary Biologics with the Initial Focus Being Exo Elixir(TM)
https://vimeo.com/653128939
Get ready for parent company AMTD to run!
> I am seeing shortages of Shell and Mobil diesel engine oil … “Force Majeure” by some suppliers, such as major USA Lubricant additive company Lubrizol > anti-corrosion agents, dispersing additives, antirust mechanisms, friction modifiers, EP additives, antifoaming agents, antioxidants, etc.
Without these additives, diesel engine oil manufacturers cannot produce the final oil products that lubricate diesel engines. Because key manufacturers of these additives have ceased operations, diesel engine oil can apparently no longer be produced , at least not until these necessary chemicals are restored to full supply.
Diesel engine truck fleets, Railroad diesel engines, and farm tractors, and harvest combines have diesel engines.
Agree! Bitcoin is surging this morning!
I have no clue what Nancy is saying. No wonder her DWI husband gets liquored up , leaves San Francisco and heads to Napa Valley.
Aaron Judge > #41 HR is grand slam in 8th inning. > 89 RBI.
NEW YORK -- Aaron Judge became the first player in the majors with 40 home runs this season with a two-run drive for the New York Yankees against the Kansas City Royals on Friday night.
The 6-foot-7 Judge robbed a home run from MJ Melendez to begin the game, and then hit an estimated 449-foot homer in the third inning for a 3-0 lead. It was his second homer in three at-bats after he hit a game-ending drive in the ninth inning of a 1-0 win against Kansas City on Thursday night.
TSLA share accumulation continues Monday!
That time share is called Huntersville. It looks like a glass cage for hamsters! What idiotic concept!
HKD closes @ 400..25 > Should see AMTD rarchet up Monday.
AMTD $$$ SHOULD ROCK TO $10.00+..EASILY....LOOK AT HKD..
HKD is a unit of AMTD IDEA Group, which has said it is transforming "from a traditional-financial-services play" by expanding in categories like the metaverse.
The former chief editor of the Chinese Communist Party's state tabloid, the Global Times, suggested the country shoot down U.S. Speaker of the House Nancy Pelosi for visiting Taiwan if her plane refuses to divert course.
China's government has warned it will take "forceful measures" if Pelosi visits Taiwan after the Financial Times reported she would travel to the Chinese-claimed island nation next month.
Hu Xijin, former chief editor of the Global Times, called Pelosi's planned visit an "invasion," and suggested shooting down the speaker's plane if U.S. fighter jets escort it to Taiwan.
How will HKD shareholders respond: The former chief editor of the Chinese Communist Party's state tabloid, the Global Times, suggested the country shoot down U.S. Speaker of the House Nancy Pelosi for visiting Taiwan if her plane refuses to divert course.
China's government has warned it will take "forceful measures" if Pelosi visits Taiwan after the Financial Times reported she would travel to the Chinese-claimed island nation next month.
Hu Xijin, former chief editor of the Global Times, called Pelosi's planned visit an "invasion," and suggested shooting down the speaker's plane if U.S. fighter jets escort it to Taiwan.
The Hong Kong-based developer of digital platforms continues a roller coaster ride. Up over 200% today!
AMTD Digital Inc is an investment holding company principally engaged in the provision of digital solutions platform. Along with subsidiaries, the Company operates its business through three segments. The SpiderNet Ecosystem Solutions segment develops digital solutions platform, provides AMTD SpiderNet ecosystem to entrepreneurs and corporates with capital, technologies, mentorship, connectivity, and other resources. The Corporate segment creates and promotes digital solutions content by investing and developing multimedia channels, and invests in technology companies. The Digital Financial Services segment provides digital financial services for retail and corporate clients, provides corporate insurance solution and digital insurance technology platform.
This security is an American depositary receipt
fwiw, TBLT is looming large on ihub buzz cloud & ihub breakout board.
I will have to visit Lowe's and Home Depot this weekend. Check on availability of ToughBuilt inventory. Will TBLT have an upcoming PR involving the "large box " hardware stores?
I will have to visit Lowe's and Home Depot this weekend. Check on availability of ToughBuilt inventory. Will TBLT have an upcoming PR involving the "large box " hardware stores?
Once we hit $50.00+ a share > I will buy a ToughBuilt tool belt . Load that belt up with Benjamins !!!!!
Agree! So many positive catalysts with the fundamentals. + Way oversold, with short positions now covering.
Next week we see the tutes such as pension plans , mutual funds, and University endowment funds accumulating shares. imo.
$TBLT 9.36 will be HUGE and $20's next week IMO
TBLT > GOING GANGBUSTERS!!!!! > $$$$$
Wow! ..... btw, TBLT > new hod @ 8.96
$TBLT thanks, I have it in all 14 accounts I manage
San Francisco Declares State Of Emergency Over Monkeypox
https://truthpress.com/news/san-francisco-declares-state-of-emergency-over-monkeypox/
San Francisco on Thursday declared a state of emergency over monkeypox.
The mayor of San Francisco declared a state of emergency after the city reported 261 cases of monkeypox.
The emergency declaration will take effect on Monday.
SF Gate reported:
The mayor of San Francisco announced a legal state of emergency Thursday over the growing number of monkeypox cases, allowing officials to mobilize personnel and resources and cut through red tape to get ahead of a public health crisis reminiscent of the AIDS epidemic that devastated the city.
The declaration, which takes effect Monday, was welcomed by gay advocates who have grown increasingly frustrated by what they called San Francisco’s lackluster response to a virus that so far has affected primarily men who have sex with men, although anyone can get infected.
The city has 261 cases, out of about 800 in California and 4,600 nationwide, according to the San Francisco Department of Public Health. A national shortage of vaccine has resulted in people waiting in line for hours for scarce doses, often to be turned away when the shots run out.
The Centers for Disease Control and Prevention (CDC) confirmed on Friday the first two U.S. cases of monkeypox in children, both adjacent to the gay community.
In a statement, the agency said that both cases are “likely the result of household transmission” and “had no contact with each other.”
“One is a toddler who lives in California, and the other is an infant who is not a resident of the U.S. and was “transiting through” the Washington, D.C. area when the test was done,” as reported by CBS News.
According to CDC, “young children (<8 years of age), individuals who are pregnant or immunocompromised, and individuals with a history of atopic dermatitis or eczema may be at especially increased risk for severe outcomes from monkeypox disease.”
It is still unknown how these children became infected with monkeypox, a disease that is most commonly transferred among gay men.
Per CDC, monkeypox is transmitted by symptomatic individuals through close contact with lesions, bodily fluids, or respiratory secretions and objects that have had contact with lesion crusts or bodily fluids, face-to-face contact, or during intimate physical contact, such as kissing, cuddling, or sex.
The media and health experts discuss the obvious — refrain from gay orgies for a few weeks to be safe.
GOVX > San Francisco Declares State Of Emergency Over Monkeypox
https://truthpress.com/news/san-francisco-declares-state-of-emergency-over-monkeypox/
San Francisco on Thursday declared a state of emergency over monkeypox.
The mayor of San Francisco declared a state of emergency after the city reported 261 cases of monkeypox.
The emergency declaration will take effect on Monday.
SF Gate reported:
The mayor of San Francisco announced a legal state of emergency Thursday over the growing number of monkeypox cases, allowing officials to mobilize personnel and resources and cut through red tape to get ahead of a public health crisis reminiscent of the AIDS epidemic that devastated the city.
The declaration, which takes effect Monday, was welcomed by gay advocates who have grown increasingly frustrated by what they called San Francisco’s lackluster response to a virus that so far has affected primarily men who have sex with men, although anyone can get infected.
The city has 261 cases, out of about 800 in California and 4,600 nationwide, according to the San Francisco Department of Public Health. A national shortage of vaccine has resulted in people waiting in line for hours for scarce doses, often to be turned away when the shots run out.
The Centers for Disease Control and Prevention (CDC) confirmed on Friday the first two U.S. cases of monkeypox in children, both adjacent to the gay community.
In a statement, the agency said that both cases are “likely the result of household transmission” and “had no contact with each other.”
“One is a toddler who lives in California, and the other is an infant who is not a resident of the U.S. and was “transiting through” the Washington, D.C. area when the test was done,” as reported by CBS News.
According to CDC, “young children (<8 years of age), individuals who are pregnant or immunocompromised, and individuals with a history of atopic dermatitis or eczema may be at especially increased risk for severe outcomes from monkeypox disease.”
It is still unknown how these children became infected with monkeypox, a disease that is most commonly transferred among gay men.
Per CDC, monkeypox is transmitted by symptomatic individuals through close contact with lesions, bodily fluids, or respiratory secretions and objects that have had contact with lesion crusts or bodily fluids, face-to-face contact, or during intimate physical contact, such as kissing, cuddling, or sex.
The media and health experts discuss the obvious — refrain from gay orgies for a few weeks to be safe.
Top Headlines > Nasdaq surges 150 points and Apple posts upbeat results.
Shares of ToughBuilt Industries, Inc. (NASDAQ: TBLT) got a boost, shooting 24% to $7.27. The company entered into an agreement with Ace Hardware USA to sell 35 products across 5,500 stores.
I have 18k shares and averaged in @ 5.24 > massive short squeeze in progress!
35M+ volume.
Nice accumulation for you!
$TBLT added 4000 shares at 7.34